Related Experiment Videos
[The sensitivity to the preparation cefotaxime of bacteria isolated from newborn infants]
Insights
Neonatal bacterial infections caused by Staphylococcus aureus and Escherichia coli showed high resistance to ampicilin and cephamandol. Cefotaxime demonstrated significant effectiveness against these pathogens in neonates.
Area of Science:
- Medical Microbiology
- Neonatal Infectious Diseases
- Antimicrobial Resistance
Background:
- Neonatal infections pose a significant threat to infant health.
- Antibiotic resistance in common neonatal pathogens like Staphylococcus aureus and Escherichia coli is a growing concern.
- Limited data exists on the efficacy of specific antibiotics against these bacteria in the neonatal population.
Purpose of the Study:
- To evaluate the antibiotic susceptibility of Staphylococcus aureus and Escherichia coli strains isolated from neonates.
- To determine the effectiveness of ampicilin, cephamandol, and cefotaxime against these neonatal bacterial isolates.
- To assess the tolerance and impact of cefotaxime on neonatal gut flora.
Main Methods:
- Isolation and identification of bacterial strains (Staphylococcus aureus and Escherichia coli) from neonates.
- Antimicrobial susceptibility testing using Kirby-Bauer disk diffusion or broth microdilution methods.
- Clinical observation of neonates treated with cefotaxime for tolerance and effects on intestinal flora.
Main Results:
- High resistance rates were observed for ampicilin (85.5% S. aureus, 80% E. coli) and cephamandol (51% S. aureus, 53.4% E. coli).
- Cefotaxime showed high sensitivity rates: 87% for S. aureus and 92.3% for E. coli.
- Cefotaxime was well-tolerated by neonates and did not suppress normal intestinal bacterial flora.
Conclusions:
- Cefotaxime is a highly effective antibiotic against common neonatal bacterial pathogens, Staphylococcus aureus and Escherichia coli.
- The observed resistance to ampicilin and cephamandol highlights the need for careful antibiotic selection in neonatal care.
- Cefotaxime presents a favorable safety profile for use in neonates, with good tolerance and minimal disruption to gut microbiota.
Abstract:
Four hundred forty-four of S. aureus and 54 strains of E. coli were isolated from the neonates, born during the first six months of 1994 in the Maternity Hospital "Maĭchin dom". They were tested with the antibiotics--ampicilin, cephamandol and cefotaxime. Our results showed that 14.5% of the tested S. aureus were sensitive to ampicilin (e.g. broad-spectrum penicillins) and 85.5% resistant. Twenty percent of the strains E. coli were sensitive to ampicilin and 80% showed resistance. Fourty nine percent of the tested S. aureus were sensitive to cephamandol (a second generation cephalosporine) and 51% were resistant; 46.6% of the isolated strains E. coli were sensitive to cephamandol and 53.4% were resistant. Over 87% of the tested S. aureus were sensitive to cefotaxime, a third generation cephalosporine, and only 13% were resistant. From the tested strains E. coli 92.3% were sensitive to cefotaxime and 7.7% were resistant. The present study proved a high sensitivity of the isolated strains to cefotaxime. In addition this antibacterial drug showed good tolerance by the neonates when given in two doses per day and a lack of suppressive effect on the normal bacterial flora of the intestinal tract of the neonates.